Cargando…

Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with t...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Souza, Ryan S., Her, Yeng F., Jin, Max Y., Morsi, Mahmoud, Abd-Elsayed, Alaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405804/
https://www.ncbi.nlm.nih.gov/pubmed/36009456
http://dx.doi.org/10.3390/biomedicines10081909
_version_ 1784773967020556288
author D’Souza, Ryan S.
Her, Yeng F.
Jin, Max Y.
Morsi, Mahmoud
Abd-Elsayed, Alaa
author_facet D’Souza, Ryan S.
Her, Yeng F.
Jin, Max Y.
Morsi, Mahmoud
Abd-Elsayed, Alaa
author_sort D’Souza, Ryan S.
collection PubMed
description Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted.
format Online
Article
Text
id pubmed-9405804
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94058042022-08-26 Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review D’Souza, Ryan S. Her, Yeng F. Jin, Max Y. Morsi, Mahmoud Abd-Elsayed, Alaa Biomedicines Systematic Review Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted. MDPI 2022-08-07 /pmc/articles/PMC9405804/ /pubmed/36009456 http://dx.doi.org/10.3390/biomedicines10081909 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
D’Souza, Ryan S.
Her, Yeng F.
Jin, Max Y.
Morsi, Mahmoud
Abd-Elsayed, Alaa
Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title_full Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title_fullStr Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title_full_unstemmed Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title_short Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review
title_sort neuromodulation therapy for chemotherapy-induced peripheral neuropathy: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405804/
https://www.ncbi.nlm.nih.gov/pubmed/36009456
http://dx.doi.org/10.3390/biomedicines10081909
work_keys_str_mv AT dsouzaryans neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview
AT heryengf neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview
AT jinmaxy neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview
AT morsimahmoud neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview
AT abdelsayedalaa neuromodulationtherapyforchemotherapyinducedperipheralneuropathyasystematicreview